미국의 단백질 표지 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the united states protein labeling market size was valued at USD 1.20 billion in 2025 and is estimated to grow from USD 1.30 billion in 2026 to reach USD 1.96 billion by 2031, at a CAGR of 8.52% during the forecast period (2026-2031).

This report is Segmented by Product (Reagents and Kits, Services, Consumables), Application (Immunological Techniques, Cell-Based Assays, Fluorescence Microscopy, Protein Microarrays, Mass Spectrometry), Labeling Method (In-Vitro, In-Vivo), and End User (Pharma and Biotech, Crdmos, Academic Institutes, Clinical Diagnostics Labs). The Market Forecasts are Provided in Terms of Value (USD).

United States Protein Labeling Market Trends and Insights

Expansion of Proteomics and Multi-Omics Pipelines

Proteomics is moving past an aspirational phase because population-scale protein profiling is becoming operationally feasible across translational research programs. UltraPlex-TMT, published in 2026, enables 58-plex pseudo-multiplexed analysis through orthogonal protease digestion, which lifts the number of samples handled in one LC-MS run without extra instrumentation. That throughput shift increases the number of labeling reagent sets used in each campaign because more samples can be tagged and processed in the same time window. It also raises demand for affinity enrichment materials such as biotinylated probes and crosslinkers that help isolate low-abundance targets before mass spectrometry readout. Multi-omics programs further increase reagent intensity because proteomic outputs need compatible and orthogonal chemistries across genomic and metabolomic assays. Thermo Fisher Scientific's 2026 Orbitrap Tribrid Apex launch adds AI-enabled software that converts raw spectra into usable proteomic readouts at scale, which deepens the role of high-purity reagents in the US protein labeling market.

Growing Use in ADC and Targeted Protein Degradation Workflows

ADC development has changed protein labeling from a routine analytical step into a precision manufacturing requirement across many drug programs. Lonza integrated GlycoConnect, HydraSpace, and toxSYN into one Advanced Synthesis platform in February 2026 and expanded the stack to dual-payload ADC formats, which shows how tightly defined conjugation has become for next-generation constructs. This shift matters because drug-to-antibody ratio control and conjugation site definition are now central to late-stage development, which reduces the commercial relevance of random-labeling chemistries in regulated settings. Targeted protein degradation adds a second demand stream because each degrader design requires separate labeling of the E3 ligase recruiting and target-binding modules to confirm cellular engagement in live-cell assays. A single program can therefore consume site-specific conjugation kits, fluorescent probes, and mass-tag quantification reagents in parallel rather than one after another. That pattern shortens procurement cycles and makes supplier relationships more durable across the US protein labeling market.

High Cost of High-Resolution Mass Spectrometry Workflows

High-resolution quantitative proteomics still carries a cost base that many academic and clinical labs cannot absorb. Orbitrap and time-of-flight instruments cost USD 500,000 to USD 1.5 million per unit, and full deployment also requires premium labeling kits, chromatography systems, and specialized software. That cost profile keeps many institutions on western blot and ELISA workflows that generate less information but require lower up-front spending. The limitation continues after instrument purchase because next-generation multiplex tag kits still carry meaningful per-experiment costs that can reduce run frequency. A shortage of bioinformatic staff adds another barrier because reagent investments are less valuable when complex DIA outputs cannot be interpreted quickly. This restraint caps spending in lower-budget segments and slows the pace at which the US protein labeling market can convert broad academic interest into full-workflow adoption.

Other drivers and restraints analyzed in the detailed report include:

1. Rising Outsourcing of Complex Conjugation to CROs and CDMOs
2. Shift Toward Site-Specific and Bioorthogonal Labeling
3. Regulatory Complexity for Radio-Isotope Conjugates

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Reagents and Kits captured 70.31% of US protein labeling market share in 2025, which gave them the leading position in the US protein labeling market. Their scale reflects entrenched use across immunoassays, proteomics platforms, and biopharmaceutical quality control laboratories where standardized kit protocols reduce experimental variability. Brand validation also supports pricing because laboratories often prefer trusted fluorescent dyes, biotin capture systems, and mass-tag kits when failed runs are costly. Consumables serve the same workflows through purification columns, gels, and plate formats that support processing after labeling. Even though consumables carry less pricing power, their reorder pattern stays tied to sample throughput and keeps them important inside the US protein labeling industry.

Services are projected to expand at a 10.38% CAGR through 2031, making them the fastest-growing product segment in the US protein labeling market. GenScript launched the TurboCHO Protein Expression Kit in May 2026 with output in 3 to 5 days and yields up to 5 times higher than competing formats, reflecting how service buyers now expect outsourced partners to reduce discovery timelines rather than only execute isolated steps. As bioorthogonal and site-specific methods become harder to run internally, custom conjugation orders are increasingly turning into recurring program agreements. That shift makes service revenue less exposed to short-term demand swings and gives specialist providers room to sustain premium margins.

Immunological Techniques accounted for 34.24% of the US protein labeling market size in 2025, which kept them as the largest application area in the US protein labeling market. ELISA, western blot, and immunohistochemistry remain durable because they sit inside established laboratory SOPs, pathology routines, and lot-release testing systems. That installed-base effect limits substitution even as newer readouts gain visibility. Mass spectrometry also holds a meaningful place, but its expansion is moderated by instrument and informatics costs already weighing on adoption. Fluorescence microscopy and protein microarrays continue to serve specific niches in localization studies and multiplex profiling with steady demand tied to system upgrades and platform refresh cycles.

Cell-based Assays are projected to grow at a 10.52% CAGR through 2031, which gives them the fastest pace within applications and expands the US protein labeling market into more live-system workflows. Merck and Promega combined Duolink proximity ligation assay technology with HiBIT split-luciferase reporters, creating a system that can detect protein-protein interactions and quantify target protein levels in 3D cell models. Organoid-based testing is also adding demand because tissue-like models need volumetric labeling approaches rather than simple surface staining. That requirement opens space for premium cell-permeant probes and enzymatic tags that standard kits do not address well.

Complete Report Scope:

• By Product
  • Reagents and Kits
  • Services
  • Consumables
• By Application
  • Immunological Techniques
  • Cell-based Assays
  • Fluorescence Microscopy
  • Protein Microarrays
  • Mass Spectrometry
• By Labeling Method
  • In-vitro Labeling
  • In-vivo Labeling
• By End User
  • Pharmaceutical and Biotechnology Companies
  • Contract Research and Development / Manufacturing Organizations
  • Academic and Research Institutes
  • Clinical Diagnostics Laboratories

List of Companies Covered in this Report:

1. Abcam
2. Agilent Technologies
3. Bio-Rad Laboratories
4. Bio-Techne
5. Biotium Inc.
6. Cell Signaling Technology
7. Creative Diagnostics
8. Danaher
9. Roche
10. Genscript
11. LI-COR Biosciences
12. Lonza Group
13. Lumiprobe Corporation
14. Merck
15. New England Biolabs
16. Promega
17. Proteintech Group
18. Revvity Inc.
19. Sartorius
20. Takara Bio
21. Thermo Fisher Scientific
22. Vector Laboratories
23. Wuxi Biologics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Expansion of proteomics and multi-omics pipelines
  • 4.2.2 Growing use in ADC and targeted protein degradation workflows
  • 4.2.3 Rising outsourcing of complex conjugation to CROs and CDMOs
  • 4.2.4 Shift toward site-specific and bioorthogonal labeling
  • 4.2.5 AI-assisted probe design for multiplex imaging
  • 4.2.6 Single-day organ-scale in-tissue labeling platforms
• 4.3 Market Restraints
  • 4.3.1 High cost of high-resolution mass spectrometry workflows
  • 4.3.2 Regulatory complexity for radio-isotope conjugates
  • 4.3.3 Dye stability and cold-chain burden
  • 4.3.4 Large-tag steric hindrance and localization artifacts
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product
  • 5.1.1 Reagents and Kits
  • 5.1.2 Services
  • 5.1.3 Consumables
• 5.2 By Application
  • 5.2.1 Immunological Techniques
  • 5.2.2 Cell-based Assays
  • 5.2.3 Fluorescence Microscopy
  • 5.2.4 Protein Microarrays
  • 5.2.5 Mass Spectrometry
• 5.3 By Labeling Method
  • 5.3.1 In-vitro Labeling
  • 5.3.2 In-vivo Labeling
• 5.4 By End User
  • 5.4.1 Pharmaceutical and Biotechnology Companies
  • 5.4.2 Contract Research and Development / Manufacturing Organizations
  • 5.4.3 Academic and Research Institutes
  • 5.4.4 Clinical Diagnostics Laboratories

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Abcam plc
  • 6.3.2 Agilent Technologies Inc.
  • 6.3.3 Bio-Rad Laboratories Inc.
  • 6.3.4 Bio-Techne Corporation
  • 6.3.5 Biotium Inc.
  • 6.3.6 Cell Signaling Technology
  • 6.3.7 Creative Diagnostics
  • 6.3.8 Danaher Corporation
  • 6.3.9 F. Hoffmann-La Roche Ltd.
  • 6.3.10 GenScript Biotech Corporation
  • 6.3.11 LI-COR Biosciences
  • 6.3.12 Lonza Group AG
  • 6.3.13 Lumiprobe Corporation
  • 6.3.14 Merck KGaA
  • 6.3.15 New England Biolabs Inc.
  • 6.3.16 Promega Corporation
  • 6.3.17 Proteintech Group
  • 6.3.18 Revvity Inc.
  • 6.3.19 Sartorius AG
  • 6.3.20 Takara Bio Inc.
  • 6.3.21 Thermo Fisher Scientific Inc.
  • 6.3.22 Vector Laboratories Inc.
  • 6.3.23 WuXi Biologics

7 Market Opportunities & Future Outlook

• 7.1 White-space and Unmet-Need Assessment